慢性肾脏病非透析患者脑钠肽前体异常的危险因素分析

金德伟; 陶敏; 马晓燕; 王奕; 盛丽莉; 刘娜

doi:10.16766/j.cnki.issn.1674-4152.002049

慢性肾脏病非透析患者脑钠肽前体异常的危险因素分析

doi: 10.16766/j.cnki.issn.1674-4152.002049

同济大学附属东方医院肾内科，上海 200092

基金项目:

国家自然科学基金项目 81670690

国家自然科学基金项目 81470991

国家自然科学基金项目 81200492

上海市自然基金项目 20ZR1445800

浦东新区重点学科附带课题 PWZxk2017-05

详细信息

通讯作者:
刘娜，E-mail：naliubrown@163.com

中图分类号: R692
计量
- 文章访问数: 302
- HTML全文浏览量: 61
- PDF下载量: 13
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-08
- 网络出版日期: 2022-02-16

Study on risk factors of N-terminal pro-brain natriuretic peptide abnormalities in non-dialysis patients with chronic kidney disease

Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200092, China

摘要

摘要: 目的研究慢性肾脏病(chronic kidney disease, CKD)非透析患者氨基末端脑钠肽前体(N-terminal pro-brain natriuretic peptide, NT-proBNP)异常的危险因素。方法选取2018年1月1日—2019年12月31日在东方医院肾内科入院治疗的259例CKD非透析患者。根据患者NT-proBNP水平将患者分为NT-proBNP正常组(Ⅰ组：NT-proBNP＜125 ng/L)和NT-proBNP异常组(Ⅱ组：NT-proBNP≥125 ng/L)，其中Ⅰ组患者129例，Ⅱ组患者130例。采用多因素logistic回归、ROC曲线分析患者NT-proBNP异常的影响因素。结果 Logistic回归分析显示高龄(P=0.008)为NT-proBNP异常的独立危险因素，高血红蛋白(P=0.014)、eGFR(P < 0.001)水平为患者NT-proBNP异常的保护因素。ROC分析显示, 当患者年龄>75.5岁(AUC=0.658, P < 0.001), 血红蛋白 < 124.5 g/L(AUC=0.769, P < 0.001), eGFR < 47.53 mL/(min·1.73 m²)(AUC=0.810, P < 0.001)时, 患者发生NT-proBNP增高的风险将显著增加。结论高龄为NT-proBNP异常的独立危险因素，高水平血红蛋白、eGFR是患者NT-proBNP异常的保护因素。
- 慢性肾脏病 /
- 氨基末端脑钠肽前体 /
- 危险因素
Abstract: Objective To investigate the risk factors of N-terminal pro-brain natriuretic peptide (NT-proBNP) abnormalities in non-dialysis patients with chronic kidney disease (CKD). Methods Non-dialysis patients hospitalized in the Department of Nephrology from January 1, 2018 to December 31, 2019 at the Shanghai East Hospital were enrolled. According to the level of NT-proBNP, patients were divided into NT-proBNP normal group (Ⅰ: NT-proBNP < 125 ng/L) and NT-proBNP abnormal group (Ⅱ: NT-proBNP≥125 ng/L). There were 129 patients in group Ⅰ and 130 patients in group Ⅱ. Multivariate Logistic regression and ROC curve were used to analyze the influencing factors of patients' NT-proBNP abnormalities. Results Logistic regression showed that age (P=0.008) was an independent risk factor for NT-proBNP abnormality, and hemoglobin (P=0.014) and eGFR (P < 0.001) were protective factors for patients with NT-proBNP abnormality. ROC analysis showed that when the patient's age was>75.5 years (AUC=0.658, P < 0.001), hemoglobin < 124.5 g/L (AUC=0.769, P < 0.001), eGFR < 47.5 [mL/(min·1.73 m²)] (AUC=0.810, P < 0.001), the risk of NT-proBNP increase will increase significantly. Conclusion Age is an independent risk factor for the increase of NT-proBNP, while hemoglobin and eGFR are protective factors.
- Chronic kidney disease /
- N-terminal pro-brain natriuretic peptide /
- Risk factor

HTML全文

表 1 2组CKD非透析患者基本临床资料比较

组别	例数	性别[例(%)]		年龄(x ±s，岁)	BMI (x ±s)	吸烟[例(%)]	饮酒[例(%)]	收缩压(x ±s，mm Hg)	舒张压(x ±s，mm Hg)	心率(x ±s，次/min)	UACR [M(P₂₅, P₇₅), mg/g]
组别	例数	男性	女性	年龄(x ±s，岁)	BMI (x ±s)	吸烟[例(%)]	饮酒[例(%)]	收缩压(x ±s，mm Hg)	舒张压(x ±s，mm Hg)	心率(x ±s，次/min)	UACR [M(P₂₅, P₇₅), mg/g]
Ⅰ组	129	82(63.6)	47(36.4)	54.8±15.4	25.0±3.4	24(18.6)	16(12.4)	144.5±91.4	84.5±12.8	80.65±14.2	307.5(91.1, 1 277.6)
Ⅱ组	130	72(55.4)	58(44.6)	63.8±14.8	24.5±4.4	27(20.8)	21(16.2)	144.8±23.5	85.3±13.2	80.3±13.2	1 218.8(161.6, 3 560.3)
统计量		1.798^a		-4.829^b	1.062^b	0.192^a	0.744^a	-0.038^b	-0.527^b	0.206^b	10 510.000^c
P值		0.180		< 0.001	0.289	0.661	0.388	0.970	0.599	0.837	< 0.001

组别	例数	24小时尿蛋白定量[M(P₂₅, P₇₅), g]		血红蛋白(x ±s，g/L)	白蛋白[M(P₂₅, P₇₅), g/L]		ALT [M(P₂₅, P₇₅), U/L]	AST [M(P₂₅, P₇₅), U/L]		SUA (x ±s，μmol/L)	eGFR[x ±s，mL/(min·1.73 m²)]
Ⅰ组	129	0.7(0.3, 2.2)		131.3±22.2	40.7(35.5, 44.2)		18.0(13.5, 25.0)	18.0(15.0, 23.0)		378.6±104.5	73.2±26.0
Ⅱ组	130	1.8(0.3, 3.7)		108.3±26.2	36.7(30.6, 40.1)		13.5(10.0, 20.0)	17.0(14.0, 24.0)		410.4±112.5	40.6±26.4
统计量		9 651.500^c		7.632^b	5 764.000^c		5 924.500^c	7 647.500^c		-2.354^b	10.001^b
P值		0.036		< 0.001	< 0.001		< 0.001	0.220		0.019	< 0.001

组别	例数	空腹血糖[M(P₂₅, P₇₅), mmol/L]		糖化血红蛋白[M(P₂₅, P₇₅), %]	疾病史[例(%)]				用药史[例(%)]
组别	例数	空腹血糖[M(P₂₅, P₇₅), mmol/L]		糖化血红蛋白[M(P₂₅, P₇₅), %]	高血压	糖尿病	冠心病		钙离子拮抗剂	ACEI/ARB	降糖药
Ⅰ组	129	5.3(4.9, 6.5)		5.8(5.4, 6.6)	87(67.4)	38(29.5)	10(7.8)		51(39.5)	77(59.7)	33(25.6)
Ⅱ组	130	5.1(4.6, 5.9)		5.8(5.3, 6.5)	108(83.1)	46(35.4)	19(14.6)		75(57.7)	76(58.5)	42(32.3)
统计量		6 632.000^c		8 254.000^c	8.508^a	1.038^a	3.068^a		8.545^a	0.040^a	1.424^a
P值		0.004		0.828	0.004	0.308	0.080		0.003	0.841	0.233
注：^a为χ²值；^b为t值；^c为U值。

下载: 导出CSV

表 2 NT-proBNP异常升高的多因素logistic回归分析

因素	B	SE	Wald χ²	P值	OR(95% CI)
年龄(岁)	0.032	0.012	7.135	0.008	1.033(1.009~1.057)
UACR(mg/g)	< 0.001	< 0.001	0.420	0.517	1.000(1.000~1.000)
24小时尿蛋白定量(g)	0.092	0.080	1.309	0.253	1.096(0.937~1.282)
血红蛋白(g/L)	0.021	0.009	6.005	0.014	0.979(0.963~0.996)
白蛋白(g/L)	0.032	0.027	1.344	0.246	0.969(0.918~1.022)
ALT(U/L)	0.003	0.010	0.072	0.789	1.003(0.983~1.023)
SUA (μmol/L)	0.001	0.002	0.091	0.763	1.001(0.997~1.004)
eGFR[mL/(min·1.73 m²)]	0.034	0.008	19.272	< 0.001	0.966(0.952~0.981)
空腹血糖(mmol/L)	0.131	0.072	3.263	0.071	0.877(0.761~1.011)
高血压	0.218	0.451	0.232	0.630	1.243(0.513~3.011)
钙离子拮抗剂	0.206	0.382	0.289	0.591	1.228(0.581~2.600)

下载: 导出CSV

参考文献(24)

[1]	ROMAGNANI P, REMUZZI G, GLASSOCK R, et al. Chronic kidney disease[J]. Nat Rev Dis Primers, 2017, 3: 17088. doi: 10.1038/nrdp.2017.88
[2]	SONG Y, LOBENE A J, WANG Y, et al. The dash diet and cardiometabolic health and chronic kidney disease: A narrative review of the evidence in east asian countries[J]. Nutrients, 2021, 13(3): 984. doi: 10.3390/nu13030984
[3]	陈建峰, 李莹. 上海市浦东城乡老年人估算肾小球滤过率及危险因素分析[J]. 中华全科医学, 2017, 15(5): 823-826. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201705030.htm
[4]	GREGG L P, HEDAYATI S S. Management of traditional cardiovascular risk factors in ckd: What are the data?[J]. Am J Kidney Dis, 2018, 72(5): 728-744. doi: 10.1053/j.ajkd.2017.12.007
[5]	SUN B, MENG M, WEI J, et al. Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure[J]. Exp Ther Med, 2020, 19(5): 3348-3354.
[6]	刘俊生, 刘莉, 杨丽娟, 等. 血清iPTH、血浆BNP、NT-proBNP水平在CKD 5期患者心功能评价中的应用价值分析[J]. 中华全科医学, 2018, 16(9): 1427-1430. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201809006.htm
[7]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 10(46): 760-789. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201904009.htm
[8]	UNGER T, BORGHI C, CHARCHAR F, et al. 2020 international society of hypertension global hypertension practice guidelines[J]. Hypertension, 2020, 75(6): 1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
[9]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201804009.htm
[10]	LEI L, HE Y, GUO Z, et al. A simple nomogram to predict contrast-induced acute kidney injury in patients with congestive heart failure undergoing coronary angiography[J]. Cardiol Res Pract, 2021. DOI: 10.1155/2021/9614953.
[11]	RANGASWAMI J, BHALLA V, BLAIR J E A, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association[J]. Circulation, 2019, 139(16): e840-e878. http://www.ncbi.nlm.nih.gov/pubmed/30852913
[12]	HOUSE A A, WANNER C, SARNAK M J, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2019, 95(6): 1304-1317. doi: 10.1016/j.kint.2019.02.022
[13]	TSUJIMOTO T, KAJIO H. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease[J]. Eur J Prev Cardiol, 2018, 25(12): 1268-1277. doi: 10.1177/2047487318780035
[14]	郝黎明, 李莹, 陈建峰, 等. 托伐普坦对左室射血分数降低心衰患者预后的影响[J]. 中国临床医学, 2018, 25(6): 872-878. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201806003.htm
[15]	TANAKA A, HIRAMATSU E, WATANABE Y, et al. Efficacy of long-term treatment with tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure[J]. Ther Apher Dial, 2019, 23(4): 319-327. doi: 10.1111/1744-9987.12789
[16]	CHANG D R, YEH H C, TING I W, et al. The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality[J]. Sci Rep, 2021, 11(1): 7851. doi: 10.1038/s41598-021-86541-3
[17]	HE J, SHLIPAK M, ANDERSON A, et al. Risk factors for heart failure in patients with chronic kidney disease: The cric (chronic renal insufficiency cohort) study[J]. J Am Heart Assoc, 2017, 6(5): e005336. http://www.onacademic.com/detail/journal_1000039907823510_3eb9.html
[18]	LAWSON C A, TESTANI J M, MAMAS M, et al. Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: A UK national study[J]. Int J Cardiol, 2018, 267: 120-127. doi: 10.1016/j.ijcard.2018.04.090
[19]	KIM C J, CHOI I J, PARK H J, et al. Impact of cardiorenal anemia syndrome on short- and long-term clinical outcomes in patients hospitalized with heart failure[J]. Cardiorenal Med, 2016, 6(4): 269-278. doi: 10.1159/000443339
[20]	PORTOLÉS J, MARTÍN L, BROSETA J J, et al. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents[J]. Front Med (Lausanne), 2021, 8: 642296. http://www.researchgate.net/publication/350404338_Anemia_in_Chronic_Kidney_Disease_From_Pathophysiology_and_Current_Treatments_to_Future_Agents
[21]	EISENGA M F, EMANS M E, VAN DER PUTTEN K, et al. Epoetin beta and c-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease[J]. J Am Heart Assoc, 2019, 8(16): e011130. http://www.researchgate.net/publication/335273832_Epoetin_Beta_and_C-Terminal_Fibroblast_Growth_Factor_23_in_Patients_With_Chronic_Heart_Failure_and_Chronic_Kidney_Disease
[22]	MELAMED M L, RAPHAEL K L. Metabolic acidosis in ckd: A review of recent findings[J]. Kidney Med, 2021, 3(2): 267-277. doi: 10.1016/j.xkme.2020.12.006
[23]	SELVARAJ S, SHAH S J, OMMERBORN M J, et al. Pulmonary hypertension is associated with a higher risk of heart failure hospitalization and mortality in patients with chronic kidney disease: The jackson heart study[J]. Circ Heart Fail, 2017, 10(6): e003940. http://www.ncbi.nlm.nih.gov/pubmed/28611127
[24]	BANSAL N, ZELNICK L, GO A, et al. Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: The cric (chronic renal insufficiency cohort) study[J]. J Am Heart Assoc, 2019, 8(21): e012336. http://www.ncbi.nlm.nih.gov/pubmed/31645163